Long-term Outcome of Gastric Per-Oral Endoscopic Pyloromyotomy in Treatment of Gastroparesis

Gastric per oral endoscopic pyloromyotomy (GPOEM) is a promising treatment for gastroparesis. There are few data on the long-term outcomes of this procedure. We investigated long-term outcomes of GPOEM treatment of patients with refractory gastroparesis. We conducted a retrospective case-series stud...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Clinical gastroenterology and hepatology 2021-04, Vol.19 (4), p.816-824
Hauptverfasser: Abdelfatah, Mohamed M., Noll, Alan, Kapil, Neil, Shah, Rushikesh, Li, Lianyong, Nustas, Rosemary, Li, Baiwen, Luo, Hui, Chen, Huimin, Xia, Liang, Mekaroonkamol, Parit, Shahnavaz, Nikrad, Keilin, Steven, Willingham, Field, Christie, Jennifer, Cai, Qiang
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 824
container_issue 4
container_start_page 816
container_title Clinical gastroenterology and hepatology
container_volume 19
creator Abdelfatah, Mohamed M.
Noll, Alan
Kapil, Neil
Shah, Rushikesh
Li, Lianyong
Nustas, Rosemary
Li, Baiwen
Luo, Hui
Chen, Huimin
Xia, Liang
Mekaroonkamol, Parit
Shahnavaz, Nikrad
Keilin, Steven
Willingham, Field
Christie, Jennifer
Cai, Qiang
description Gastric per oral endoscopic pyloromyotomy (GPOEM) is a promising treatment for gastroparesis. There are few data on the long-term outcomes of this procedure. We investigated long-term outcomes of GPOEM treatment of patients with refractory gastroparesis. We conducted a retrospective case-series study of all patients who underwent GPOEM for refractory gastroparesis at a single center (n = 97), from June 2015 through March 2019; 90 patients had more than 3 months follow-up data and were included in our final analysis. We collected data on gastroparesis cardinal symptom index (GCSI) scores (measurements of postprandial fullness or early satiety, nausea and vomiting, and bloating) and SF-36 questionnaire scores (measures quality of life). The primary outcome was clinical response to GPOEM, defined as a decrease of at least 1 point in the average total GCSI score with more than a 25% decrease in at least 2 subscales of cardinal symptoms. Recurrence was defined as a return to baseline GCSI or GCSI scores of 3 or more for at least 2 months after an initial complete response. The secondary outcome was the factors that predict GPOEM failure (no response or gastroparesis recurrence within 6 months). At initial follow-up (3 to 6 months after GPOEM), 73 patients (81.1%) had a clinical response and significant increases in SF-36 questionnaire scores (indicating increased quality of life) whereas 17 patients (18.9%) had no response. Six months after GPOEM, 7.1% had recurrence. At 12 months, 8.3% of patients remaining in the study had recurrence. At 24 months, 4.8% of patients remaining in the study had a recurrence. At 36 months, 14.3% of patients remaining in the study had recurrence. For patients who experienced an initial clinical response, the rate of loss of that response per year was 12.9%. In the univariate and multivariate regression analysis, a longer duration of gastroparesis reduced the odds of response to GPOEM (odds ratio [OR], 0.092; 95% CI, 1.04–1.3; P = .001). On multivariate logistic regression, patients with high BMIs had increased odds of GPOEM failure (OR, 1.097; 95% CI, 1.022–1.176; P = .010) and patients receiving psychiatric medications had a higher risk of GPOEM failure (OR, 1.33; 95% CI, 0.110–1.008; P = .052). In retrospective analysis of 90 patients who underwent GPOEM for refractory gastroparesis, 81.1% had a clinical response at initial follow-up of their procedure. 1 year after GPOEM, 69.1% of all patients had a clinical response and 85.2%
doi_str_mv 10.1016/j.cgh.2020.05.039
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2406947180</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S154235652030700X</els_id><sourcerecordid>2406947180</sourcerecordid><originalsourceid>FETCH-LOGICAL-c396t-3ac6275edd2545471eefe7e196c5bd868f21e100a1cf8179a4cc9ab4ed328ad93</originalsourceid><addsrcrecordid>eNp9kEFLwzAYhoMobk5_gBfp0UtrkiZtgyeROYXBPMybELLk68xom5pkwv69HZs7evnyEd73ge9B6JbgjGBSPGwyvf7KKKY4wzzDuThDY8IZTcuSsPPjnvOCj9BVCBuMqWCivESjnDKO84KN0efcdes0gm-TxTZq10Li6mSmQvRWJ-_g04VXTTLtjAva9fu_XeO8a3cuDiOxXbL0oGILXTw1Xa88BBuu0UWtmgA3x3eCPl6my-fXdL6YvT0_zVOdiyKmudIFLTkYQznjrCQANZRARKH5ylRFVVMCBGNFdF2RUiimtVArBianlTIin6D7A7f37nsLIcrWBg1Nozpw2yApw4UYuBUeouQQ1d6F4KGWvbet8jtJsNxLlRs5SJV7qRJzOUgdOndH_HbVgjk1_iwOgcdDAIYjfyx4GbSFToOxHnSUxtl_8L98FIh3</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2406947180</pqid></control><display><type>article</type><title>Long-term Outcome of Gastric Per-Oral Endoscopic Pyloromyotomy in Treatment of Gastroparesis</title><source>Elsevier ScienceDirect Journals Complete - AutoHoldings</source><creator>Abdelfatah, Mohamed M. ; Noll, Alan ; Kapil, Neil ; Shah, Rushikesh ; Li, Lianyong ; Nustas, Rosemary ; Li, Baiwen ; Luo, Hui ; Chen, Huimin ; Xia, Liang ; Mekaroonkamol, Parit ; Shahnavaz, Nikrad ; Keilin, Steven ; Willingham, Field ; Christie, Jennifer ; Cai, Qiang</creator><creatorcontrib>Abdelfatah, Mohamed M. ; Noll, Alan ; Kapil, Neil ; Shah, Rushikesh ; Li, Lianyong ; Nustas, Rosemary ; Li, Baiwen ; Luo, Hui ; Chen, Huimin ; Xia, Liang ; Mekaroonkamol, Parit ; Shahnavaz, Nikrad ; Keilin, Steven ; Willingham, Field ; Christie, Jennifer ; Cai, Qiang</creatorcontrib><description>Gastric per oral endoscopic pyloromyotomy (GPOEM) is a promising treatment for gastroparesis. There are few data on the long-term outcomes of this procedure. We investigated long-term outcomes of GPOEM treatment of patients with refractory gastroparesis. We conducted a retrospective case-series study of all patients who underwent GPOEM for refractory gastroparesis at a single center (n = 97), from June 2015 through March 2019; 90 patients had more than 3 months follow-up data and were included in our final analysis. We collected data on gastroparesis cardinal symptom index (GCSI) scores (measurements of postprandial fullness or early satiety, nausea and vomiting, and bloating) and SF-36 questionnaire scores (measures quality of life). The primary outcome was clinical response to GPOEM, defined as a decrease of at least 1 point in the average total GCSI score with more than a 25% decrease in at least 2 subscales of cardinal symptoms. Recurrence was defined as a return to baseline GCSI or GCSI scores of 3 or more for at least 2 months after an initial complete response. The secondary outcome was the factors that predict GPOEM failure (no response or gastroparesis recurrence within 6 months). At initial follow-up (3 to 6 months after GPOEM), 73 patients (81.1%) had a clinical response and significant increases in SF-36 questionnaire scores (indicating increased quality of life) whereas 17 patients (18.9%) had no response. Six months after GPOEM, 7.1% had recurrence. At 12 months, 8.3% of patients remaining in the study had recurrence. At 24 months, 4.8% of patients remaining in the study had a recurrence. At 36 months, 14.3% of patients remaining in the study had recurrence. For patients who experienced an initial clinical response, the rate of loss of that response per year was 12.9%. In the univariate and multivariate regression analysis, a longer duration of gastroparesis reduced the odds of response to GPOEM (odds ratio [OR], 0.092; 95% CI, 1.04–1.3; P = .001). On multivariate logistic regression, patients with high BMIs had increased odds of GPOEM failure (OR, 1.097; 95% CI, 1.022–1.176; P = .010) and patients receiving psychiatric medications had a higher risk of GPOEM failure (OR, 1.33; 95% CI, 0.110–1.008; P = .052). In retrospective analysis of 90 patients who underwent GPOEM for refractory gastroparesis, 81.1% had a clinical response at initial follow-up of their procedure. 1 year after GPOEM, 69.1% of all patients had a clinical response and 85.2% of initial responders maintained a clinical response. Patients maintained a clinical response and improved quality of life for as long as 3 years after the procedure. High BMI and long duration gastroparesis were associated with failure of GPOEM.</description><identifier>ISSN: 1542-3565</identifier><identifier>EISSN: 1542-7714</identifier><identifier>DOI: 10.1016/j.cgh.2020.05.039</identifier><identifier>PMID: 32450364</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Diabetes ; Gastric Emptying ; Psychologic ; Therapy</subject><ispartof>Clinical gastroenterology and hepatology, 2021-04, Vol.19 (4), p.816-824</ispartof><rights>2021 AGA Institute</rights><rights>Copyright © 2021 AGA Institute. Published by Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c396t-3ac6275edd2545471eefe7e196c5bd868f21e100a1cf8179a4cc9ab4ed328ad93</citedby><cites>FETCH-LOGICAL-c396t-3ac6275edd2545471eefe7e196c5bd868f21e100a1cf8179a4cc9ab4ed328ad93</cites><orcidid>0000-0002-9931-5410 ; 0000-0003-0830-4634 ; 0000-0002-7071-3001</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.cgh.2020.05.039$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3541,27915,27916,45986</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32450364$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Abdelfatah, Mohamed M.</creatorcontrib><creatorcontrib>Noll, Alan</creatorcontrib><creatorcontrib>Kapil, Neil</creatorcontrib><creatorcontrib>Shah, Rushikesh</creatorcontrib><creatorcontrib>Li, Lianyong</creatorcontrib><creatorcontrib>Nustas, Rosemary</creatorcontrib><creatorcontrib>Li, Baiwen</creatorcontrib><creatorcontrib>Luo, Hui</creatorcontrib><creatorcontrib>Chen, Huimin</creatorcontrib><creatorcontrib>Xia, Liang</creatorcontrib><creatorcontrib>Mekaroonkamol, Parit</creatorcontrib><creatorcontrib>Shahnavaz, Nikrad</creatorcontrib><creatorcontrib>Keilin, Steven</creatorcontrib><creatorcontrib>Willingham, Field</creatorcontrib><creatorcontrib>Christie, Jennifer</creatorcontrib><creatorcontrib>Cai, Qiang</creatorcontrib><title>Long-term Outcome of Gastric Per-Oral Endoscopic Pyloromyotomy in Treatment of Gastroparesis</title><title>Clinical gastroenterology and hepatology</title><addtitle>Clin Gastroenterol Hepatol</addtitle><description>Gastric per oral endoscopic pyloromyotomy (GPOEM) is a promising treatment for gastroparesis. There are few data on the long-term outcomes of this procedure. We investigated long-term outcomes of GPOEM treatment of patients with refractory gastroparesis. We conducted a retrospective case-series study of all patients who underwent GPOEM for refractory gastroparesis at a single center (n = 97), from June 2015 through March 2019; 90 patients had more than 3 months follow-up data and were included in our final analysis. We collected data on gastroparesis cardinal symptom index (GCSI) scores (measurements of postprandial fullness or early satiety, nausea and vomiting, and bloating) and SF-36 questionnaire scores (measures quality of life). The primary outcome was clinical response to GPOEM, defined as a decrease of at least 1 point in the average total GCSI score with more than a 25% decrease in at least 2 subscales of cardinal symptoms. Recurrence was defined as a return to baseline GCSI or GCSI scores of 3 or more for at least 2 months after an initial complete response. The secondary outcome was the factors that predict GPOEM failure (no response or gastroparesis recurrence within 6 months). At initial follow-up (3 to 6 months after GPOEM), 73 patients (81.1%) had a clinical response and significant increases in SF-36 questionnaire scores (indicating increased quality of life) whereas 17 patients (18.9%) had no response. Six months after GPOEM, 7.1% had recurrence. At 12 months, 8.3% of patients remaining in the study had recurrence. At 24 months, 4.8% of patients remaining in the study had a recurrence. At 36 months, 14.3% of patients remaining in the study had recurrence. For patients who experienced an initial clinical response, the rate of loss of that response per year was 12.9%. In the univariate and multivariate regression analysis, a longer duration of gastroparesis reduced the odds of response to GPOEM (odds ratio [OR], 0.092; 95% CI, 1.04–1.3; P = .001). On multivariate logistic regression, patients with high BMIs had increased odds of GPOEM failure (OR, 1.097; 95% CI, 1.022–1.176; P = .010) and patients receiving psychiatric medications had a higher risk of GPOEM failure (OR, 1.33; 95% CI, 0.110–1.008; P = .052). In retrospective analysis of 90 patients who underwent GPOEM for refractory gastroparesis, 81.1% had a clinical response at initial follow-up of their procedure. 1 year after GPOEM, 69.1% of all patients had a clinical response and 85.2% of initial responders maintained a clinical response. Patients maintained a clinical response and improved quality of life for as long as 3 years after the procedure. High BMI and long duration gastroparesis were associated with failure of GPOEM.</description><subject>Diabetes</subject><subject>Gastric Emptying</subject><subject>Psychologic</subject><subject>Therapy</subject><issn>1542-3565</issn><issn>1542-7714</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><recordid>eNp9kEFLwzAYhoMobk5_gBfp0UtrkiZtgyeROYXBPMybELLk68xom5pkwv69HZs7evnyEd73ge9B6JbgjGBSPGwyvf7KKKY4wzzDuThDY8IZTcuSsPPjnvOCj9BVCBuMqWCivESjnDKO84KN0efcdes0gm-TxTZq10Li6mSmQvRWJ-_g04VXTTLtjAva9fu_XeO8a3cuDiOxXbL0oGILXTw1Xa88BBuu0UWtmgA3x3eCPl6my-fXdL6YvT0_zVOdiyKmudIFLTkYQznjrCQANZRARKH5ylRFVVMCBGNFdF2RUiimtVArBianlTIin6D7A7f37nsLIcrWBg1Nozpw2yApw4UYuBUeouQQ1d6F4KGWvbet8jtJsNxLlRs5SJV7qRJzOUgdOndH_HbVgjk1_iwOgcdDAIYjfyx4GbSFToOxHnSUxtl_8L98FIh3</recordid><startdate>202104</startdate><enddate>202104</enddate><creator>Abdelfatah, Mohamed M.</creator><creator>Noll, Alan</creator><creator>Kapil, Neil</creator><creator>Shah, Rushikesh</creator><creator>Li, Lianyong</creator><creator>Nustas, Rosemary</creator><creator>Li, Baiwen</creator><creator>Luo, Hui</creator><creator>Chen, Huimin</creator><creator>Xia, Liang</creator><creator>Mekaroonkamol, Parit</creator><creator>Shahnavaz, Nikrad</creator><creator>Keilin, Steven</creator><creator>Willingham, Field</creator><creator>Christie, Jennifer</creator><creator>Cai, Qiang</creator><general>Elsevier Inc</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-9931-5410</orcidid><orcidid>https://orcid.org/0000-0003-0830-4634</orcidid><orcidid>https://orcid.org/0000-0002-7071-3001</orcidid></search><sort><creationdate>202104</creationdate><title>Long-term Outcome of Gastric Per-Oral Endoscopic Pyloromyotomy in Treatment of Gastroparesis</title><author>Abdelfatah, Mohamed M. ; Noll, Alan ; Kapil, Neil ; Shah, Rushikesh ; Li, Lianyong ; Nustas, Rosemary ; Li, Baiwen ; Luo, Hui ; Chen, Huimin ; Xia, Liang ; Mekaroonkamol, Parit ; Shahnavaz, Nikrad ; Keilin, Steven ; Willingham, Field ; Christie, Jennifer ; Cai, Qiang</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c396t-3ac6275edd2545471eefe7e196c5bd868f21e100a1cf8179a4cc9ab4ed328ad93</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Diabetes</topic><topic>Gastric Emptying</topic><topic>Psychologic</topic><topic>Therapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Abdelfatah, Mohamed M.</creatorcontrib><creatorcontrib>Noll, Alan</creatorcontrib><creatorcontrib>Kapil, Neil</creatorcontrib><creatorcontrib>Shah, Rushikesh</creatorcontrib><creatorcontrib>Li, Lianyong</creatorcontrib><creatorcontrib>Nustas, Rosemary</creatorcontrib><creatorcontrib>Li, Baiwen</creatorcontrib><creatorcontrib>Luo, Hui</creatorcontrib><creatorcontrib>Chen, Huimin</creatorcontrib><creatorcontrib>Xia, Liang</creatorcontrib><creatorcontrib>Mekaroonkamol, Parit</creatorcontrib><creatorcontrib>Shahnavaz, Nikrad</creatorcontrib><creatorcontrib>Keilin, Steven</creatorcontrib><creatorcontrib>Willingham, Field</creatorcontrib><creatorcontrib>Christie, Jennifer</creatorcontrib><creatorcontrib>Cai, Qiang</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical gastroenterology and hepatology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Abdelfatah, Mohamed M.</au><au>Noll, Alan</au><au>Kapil, Neil</au><au>Shah, Rushikesh</au><au>Li, Lianyong</au><au>Nustas, Rosemary</au><au>Li, Baiwen</au><au>Luo, Hui</au><au>Chen, Huimin</au><au>Xia, Liang</au><au>Mekaroonkamol, Parit</au><au>Shahnavaz, Nikrad</au><au>Keilin, Steven</au><au>Willingham, Field</au><au>Christie, Jennifer</au><au>Cai, Qiang</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Long-term Outcome of Gastric Per-Oral Endoscopic Pyloromyotomy in Treatment of Gastroparesis</atitle><jtitle>Clinical gastroenterology and hepatology</jtitle><addtitle>Clin Gastroenterol Hepatol</addtitle><date>2021-04</date><risdate>2021</risdate><volume>19</volume><issue>4</issue><spage>816</spage><epage>824</epage><pages>816-824</pages><issn>1542-3565</issn><eissn>1542-7714</eissn><abstract>Gastric per oral endoscopic pyloromyotomy (GPOEM) is a promising treatment for gastroparesis. There are few data on the long-term outcomes of this procedure. We investigated long-term outcomes of GPOEM treatment of patients with refractory gastroparesis. We conducted a retrospective case-series study of all patients who underwent GPOEM for refractory gastroparesis at a single center (n = 97), from June 2015 through March 2019; 90 patients had more than 3 months follow-up data and were included in our final analysis. We collected data on gastroparesis cardinal symptom index (GCSI) scores (measurements of postprandial fullness or early satiety, nausea and vomiting, and bloating) and SF-36 questionnaire scores (measures quality of life). The primary outcome was clinical response to GPOEM, defined as a decrease of at least 1 point in the average total GCSI score with more than a 25% decrease in at least 2 subscales of cardinal symptoms. Recurrence was defined as a return to baseline GCSI or GCSI scores of 3 or more for at least 2 months after an initial complete response. The secondary outcome was the factors that predict GPOEM failure (no response or gastroparesis recurrence within 6 months). At initial follow-up (3 to 6 months after GPOEM), 73 patients (81.1%) had a clinical response and significant increases in SF-36 questionnaire scores (indicating increased quality of life) whereas 17 patients (18.9%) had no response. Six months after GPOEM, 7.1% had recurrence. At 12 months, 8.3% of patients remaining in the study had recurrence. At 24 months, 4.8% of patients remaining in the study had a recurrence. At 36 months, 14.3% of patients remaining in the study had recurrence. For patients who experienced an initial clinical response, the rate of loss of that response per year was 12.9%. In the univariate and multivariate regression analysis, a longer duration of gastroparesis reduced the odds of response to GPOEM (odds ratio [OR], 0.092; 95% CI, 1.04–1.3; P = .001). On multivariate logistic regression, patients with high BMIs had increased odds of GPOEM failure (OR, 1.097; 95% CI, 1.022–1.176; P = .010) and patients receiving psychiatric medications had a higher risk of GPOEM failure (OR, 1.33; 95% CI, 0.110–1.008; P = .052). In retrospective analysis of 90 patients who underwent GPOEM for refractory gastroparesis, 81.1% had a clinical response at initial follow-up of their procedure. 1 year after GPOEM, 69.1% of all patients had a clinical response and 85.2% of initial responders maintained a clinical response. Patients maintained a clinical response and improved quality of life for as long as 3 years after the procedure. High BMI and long duration gastroparesis were associated with failure of GPOEM.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>32450364</pmid><doi>10.1016/j.cgh.2020.05.039</doi><tpages>9</tpages><orcidid>https://orcid.org/0000-0002-9931-5410</orcidid><orcidid>https://orcid.org/0000-0003-0830-4634</orcidid><orcidid>https://orcid.org/0000-0002-7071-3001</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1542-3565
ispartof Clinical gastroenterology and hepatology, 2021-04, Vol.19 (4), p.816-824
issn 1542-3565
1542-7714
language eng
recordid cdi_proquest_miscellaneous_2406947180
source Elsevier ScienceDirect Journals Complete - AutoHoldings
subjects Diabetes
Gastric Emptying
Psychologic
Therapy
title Long-term Outcome of Gastric Per-Oral Endoscopic Pyloromyotomy in Treatment of Gastroparesis
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-15T05%3A46%3A22IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Long-term%20Outcome%20of%20Gastric%20Per-Oral%20Endoscopic%20Pyloromyotomy%20in%20Treatment%20of%20Gastroparesis&rft.jtitle=Clinical%20gastroenterology%20and%20hepatology&rft.au=Abdelfatah,%20Mohamed%20M.&rft.date=2021-04&rft.volume=19&rft.issue=4&rft.spage=816&rft.epage=824&rft.pages=816-824&rft.issn=1542-3565&rft.eissn=1542-7714&rft_id=info:doi/10.1016/j.cgh.2020.05.039&rft_dat=%3Cproquest_cross%3E2406947180%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2406947180&rft_id=info:pmid/32450364&rft_els_id=S154235652030700X&rfr_iscdi=true